Form 4: Vir Biotechnology Director Farid Ramy Acquires 16,000 Shares and Stock Options

Director Farid Ramy acquired 16,000 shares of common stock and stock options in Vir Biotechnology on May 29, 2024.

Summary

• On May 29, 2024, Farid Ramy, a director of Vir Biotechnology, acquired 16,000 shares of common stock at $0 per share.
• On the same date, Ramy also acquired stock options for 16,000 shares of common stock with an exercise price of $10.10, expiring on May 28, 2034.
• 1/3 of the shares subject to one stock option vest on May 29, 2025, with the remainder vesting in 24 equal monthly installments.
• The other stock option vests on the earlier of May 29, 2025, or the date of the company's next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the acquisition of shares at $0 suggests it may be related to compensation or a pre-existing agreement rather than a market purchase.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares and stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates